Feng Yu / Shutterstock.com
Sweden-based pharmaceutical research company BioInvent International has been granted additional patent protection for its BI-505 immune oncology programme for myeloma.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
BioInvent International, myeloma, ICAM-1, cancer, Michael Oredsson, antibody cells, BI-505, patent
